General Resources / Legal Resources / Medical
Resources / Briefing Papers / State Activity
Hospital Closures / Preventable
Tragedies / Press Room / Search
Our Site / Home
Kasapis C, Amador XF, Yale SA, Strauss D, Gorman JM.
Schizophrenia Research, 20:123,1996.
RELEVANCE FOR EARLY INTERVENTION
This paper reports on a replication of the Young et. al.,
study which implicated frontal lobe dysfunction in the etiology of poor insight in
patients with schizophrenia. The study also investigated the extent to which defensiveness
might play a role in such unawareness. The authors (XFA) had previously hypothesized that
frontal lobe pathology may account for the severe forms of unawareness frequently seen in
certain psychotic disorders. This study tested this hypothesis using the same
neuropsychological tests and insight scale used by Young and his colleagues. Defensiveness
was measured using the Balanced Inventory of Desirable Responding (BIDR). The results
indicated that defensiveness was modestly correlated with only a handful of the different
measures of poor insight. On the other hand, the neuropsychological test results were
nearly identical to that of Young and colleagues, indicating that poor performance on
tests of frontal function predicted poor insight independent of other cognitive functions
tested including IQ. This independent replication adds further evidence in support of the
idea that poor insight into illness and resulting treatment refusal stem from a mental
defect rather than defensiveness or informed choice.
General Resources / Legal Resources / Medical
Resources / Briefing Papers / State Activity
Hospital Closures / Preventable
Tragedies / Press Room / Search
Our Site / Home
The contents of all material available on the Center's website are copyrighted by the Treatment Advocacy Center unless otherwise indicated. All rights reserved and content may be reproduced, downloaded, disseminated, or transferred, for single use, or by nonprofit organizations for educational purposes only, if correct attribution is made to the Treatment Advocacy Center. Please feel free to call with questions on mental illness, treatment laws or the benefits of medication compliance at 703.294.6001 or send questions via email to [email protected]. Write to us at: The Treatment Advocacy Center; 3300 N. Fairfax Drive; Suite 220; Arlington, VA 22201. Technical comments on the Center's website (www.psychlaws.org) can be sent to [email protected]. The Treatment Advocacy Center is an I.R.C. � 501(c)(3) tax-exempt corporation. Donations are appreciated and are eligible for the charitable contribution deduction under the provisions of I.R.C. � 170. |